questionsmedicales.fr
Cellules
Cellules cultivées
Cellules cancéreuses en culture
Lignée cellulaire tumorale
Lignée cellulaire tumorale : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Lignée cellulaire
Tumeur maligne
Biopsie
Immunohistochimie
Hétérogénéité tumorale
Génétique
Recherche sur le cancer
Thérapie ciblée
Biomarqueurs
Diagnostic précoce
Symptômes
5
Symptômes du cancer
Fatigue
Modèles cellulaires
Recherche sur le cancer
Types de cancer
Symptômes spécifiques
Stade du cancer
Progression tumorale
Mécanismes pathologiques
Modèles expérimentaux
Prévention
5
Prévention du cancer
Facteurs de risque
Biomarqueurs
Recherche préventive
Agents préventifs
Tests in vitro
Environnement tumoral
Facteurs environnementaux
Recommandations de santé
Santé publique
Traitements
5
Thérapie anticancéreuse
Résistance aux médicaments
Chimiothérapie
Immunothérapie
Prédiction de réponse
Essais cliniques
Développement de médicaments
Recherche translationnelle
Recherche clinique
Applications thérapeutiques
Complications
5
Contamination
Erreurs expérimentales
Mutations
Évolution cellulaire
Protocoles de laboratoire
Manipulation cellulaire
Applications cliniques
Modèles expérimentaux
Validité des résultats
Recherche biomédicale
Facteurs de risque
5
Facteurs génétiques
Facteurs environnementaux
Mécanismes de risque
Recherche épidémiologique
Modélisation
Croissance tumorale
Interventions préventives
Tests in vitro
Risques spécifiques
Types de cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lignée cellulaire tumorale : Questions médicales les plus fréquentes",
"headline": "Lignée cellulaire tumorale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lignée cellulaire tumorale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-29",
"dateModified": "2025-03-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lignée cellulaire tumorale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cellules cancéreuses en culture",
"url": "https://questionsmedicales.fr/mesh/D014407",
"about": {
"@type": "MedicalCondition",
"name": "Cellules cancéreuses en culture",
"code": {
"@type": "MedicalCode",
"code": "D014407",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.251.860"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cellules HCT116",
"alternateName": "HCT116 Cells",
"url": "https://questionsmedicales.fr/mesh/D045325",
"about": {
"@type": "MedicalCondition",
"name": "Cellules HCT116",
"code": {
"@type": "MedicalCode",
"code": "D045325",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.251.860.180.380"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cellules MDA-MB-231",
"alternateName": "MDA-MB-231 Cells",
"url": "https://questionsmedicales.fr/mesh/D000092302",
"about": {
"@type": "MedicalCondition",
"name": "Cellules MDA-MB-231",
"code": {
"@type": "MedicalCode",
"code": "D000092302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.251.860.180.630"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cellules THP-1",
"alternateName": "THP-1 Cells",
"url": "https://questionsmedicales.fr/mesh/D000074084",
"about": {
"@type": "MedicalCondition",
"name": "Cellules THP-1",
"code": {
"@type": "MedicalCode",
"code": "D000074084",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.251.860.180.815"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Lignée cellulaire tumorale",
"alternateName": "Cell Line, Tumor",
"code": {
"@type": "MedicalCode",
"code": "D045744",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takuya Ono",
"url": "https://questionsmedicales.fr/author/Takuya%20Ono",
"affiliation": {
"@type": "Organization",
"name": "Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan."
}
},
{
"@type": "Person",
"name": "Rei Noguchi",
"url": "https://questionsmedicales.fr/author/Rei%20Noguchi",
"affiliation": {
"@type": "Organization",
"name": "Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan."
}
},
{
"@type": "Person",
"name": "Yuki Yoshimatsu",
"url": "https://questionsmedicales.fr/author/Yuki%20Yoshimatsu",
"affiliation": {
"@type": "Organization",
"name": "Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan."
}
},
{
"@type": "Person",
"name": "Ryuto Tsuchiya",
"url": "https://questionsmedicales.fr/author/Ryuto%20Tsuchiya",
"affiliation": {
"@type": "Organization",
"name": "Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan."
}
},
{
"@type": "Person",
"name": "Yooksil Sin",
"url": "https://questionsmedicales.fr/author/Yooksil%20Sin",
"affiliation": {
"@type": "Organization",
"name": "Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The effect of smoking on latent hazard classes of metabolic syndrome using latent class causal analysis method in the Iranian population.",
"datePublished": "2023-10-20",
"url": "https://questionsmedicales.fr/article/37864179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-023-16863-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Part I: A friendly introduction to latent class analysis.",
"datePublished": "2022-05-27",
"url": "https://questionsmedicales.fr/article/35636591",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jclinepi.2022.05.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Subgroups of borderline personality disorder: A latent class analysis.",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/36905903",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.psychres.2023.115131"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multimorbidity patterns in South Africa: A latent class analysis.",
"datePublished": "2023-01-11",
"url": "https://questionsmedicales.fr/article/36711391",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2022.1082587"
}
},
{
"@type": "ScholarlyArticle",
"name": "A two-step estimator for multilevel latent class analysis with covariates.",
"datePublished": "2023-08-06",
"url": "https://questionsmedicales.fr/article/37544973",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11336-023-09929-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules cultivées",
"item": "https://questionsmedicales.fr/mesh/D002478"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cellules cancéreuses en culture",
"item": "https://questionsmedicales.fr/mesh/D014407"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lignée cellulaire tumorale",
"item": "https://questionsmedicales.fr/mesh/D045744"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lignée cellulaire tumorale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lignée cellulaire tumorale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lignée cellulaire tumorale",
"description": "Comment identifier une lignée cellulaire tumorale ?\nQuels tests sont utilisés pour le diagnostic ?\nLes lignées cellulaires tumorales sont-elles toutes identiques ?\nQuel rôle jouent les lignées cellulaires dans le diagnostic ?\nPeut-on utiliser des lignées cellulaires pour le diagnostic précoce ?",
"url": "https://questionsmedicales.fr/mesh/D045744?mesh_terms=Latent+Class+Analysis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lignée cellulaire tumorale",
"description": "Quels symptômes peuvent indiquer une lignée cellulaire tumorale ?\nLes lignées cellulaires tumorales causent-elles des symptômes ?\nComment les symptômes varient-ils selon le type de cancer ?\nLes symptômes sont-ils liés à la progression de la maladie ?\nLes lignées cellulaires tumorales peuvent-elles simuler des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D045744?mesh_terms=Latent+Class+Analysis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lignée cellulaire tumorale",
"description": "Les lignées cellulaires tumorales aident-elles à la prévention du cancer ?\nComment les lignées cellulaires contribuent-elles à la recherche préventive ?\nPeut-on tester des agents préventifs sur des lignées cellulaires ?\nLes lignées cellulaires peuvent-elles simuler des environnements préventifs ?\nLes résultats des lignées cellulaires influencent-ils les recommandations de prévention ?",
"url": "https://questionsmedicales.fr/mesh/D045744?mesh_terms=Latent+Class+Analysis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lignée cellulaire tumorale",
"description": "Comment les lignées cellulaires tumorales aident-elles au traitement ?\nQuels types de traitements sont testés sur ces lignées ?\nLes lignées cellulaires prédisent-elles la réponse au traitement ?\nPeut-on développer de nouveaux traitements grâce aux lignées cellulaires ?\nLes lignées cellulaires tumorales sont-elles utilisées en clinique ?",
"url": "https://questionsmedicales.fr/mesh/D045744?mesh_terms=Latent+Class+Analysis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lignée cellulaire tumorale",
"description": "Quelles complications peuvent survenir avec les lignées cellulaires ?\nLes lignées cellulaires tumorales peuvent-elles évoluer ?\nComment gérer les complications lors de l'utilisation des lignées cellulaires ?\nLes lignées cellulaires peuvent-elles induire des complications cliniques ?\nLes complications des lignées cellulaires affectent-elles la recherche ?",
"url": "https://questionsmedicales.fr/mesh/D045744?mesh_terms=Latent+Class+Analysis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lignée cellulaire tumorale",
"description": "Quels facteurs de risque sont étudiés avec les lignées cellulaires ?\nLes lignées cellulaires peuvent-elles aider à identifier des facteurs de risque ?\nComment les lignées cellulaires contribuent-elles à la compréhension des risques ?\nPeut-on tester des interventions préventives sur des lignées cellulaires ?\nLes lignées cellulaires tumorales révèlent-elles des risques spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D045744?mesh_terms=Latent+Class+Analysis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier une lignée cellulaire tumorale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des tests histologiques et des marqueurs spécifiques de cancer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biopsies, l'immunohistochimie et la cytogénétique sont courants."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales sont-elles toutes identiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles varient selon le type de cancer et les caractéristiques génétiques."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les lignées cellulaires dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à étudier la biologie tumorale et à tester des traitements."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des lignées cellulaires pour le diagnostic précoce ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent aider à identifier des biomarqueurs pour un diagnostic précoce."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une lignée cellulaire tumorale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de cancer, incluant douleur, fatigue, et perte de poids."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales causent-elles des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont des modèles de recherche et ne causent pas de symptômes directement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le type de cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Chaque type de cancer présente des symptômes spécifiques selon l'organe affecté."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils liés à la progression de la maladie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes plus graves peuvent indiquer une progression avancée du cancer."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales peuvent-elles simuler des symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées pour étudier les mécanismes des symptômes, mais ne les simulent pas."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales aident-elles à la prévention du cancer ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les facteurs de risque et de développer des stratégies préventives."
}
},
{
"@type": "Question",
"name": "Comment les lignées cellulaires contribuent-elles à la recherche préventive ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à identifier des biomarqueurs et des cibles pour la prévention."
}
},
{
"@type": "Question",
"name": "Peut-on tester des agents préventifs sur des lignées cellulaires ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des agents chimiques ou biologiques peuvent être testés pour leur potentiel préventif."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires peuvent-elles simuler des environnements préventifs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être modifiées pour étudier l'impact de divers facteurs environnementaux."
}
},
{
"@type": "Question",
"name": "Les résultats des lignées cellulaires influencent-ils les recommandations de prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les découvertes peuvent guider les recommandations de santé publique et de prévention."
}
},
{
"@type": "Question",
"name": "Comment les lignées cellulaires tumorales aident-elles au traitement ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent de tester l'efficacité des médicaments et de comprendre la résistance."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont testés sur ces lignées ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les chimiothérapies, thérapies ciblées et immunothérapies sont couramment testées."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires prédisent-elles la réponse au traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent donner des indications, mais ne garantissent pas la réponse clinique."
}
},
{
"@type": "Question",
"name": "Peut-on développer de nouveaux traitements grâce aux lignées cellulaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour le développement et l'optimisation de nouveaux traitements."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales sont-elles utilisées en clinique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont principalement utilisées en recherche, pas directement en clinique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les lignées cellulaires ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des erreurs de culture ou des contaminations peuvent fausser les résultats expérimentaux."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales peuvent-elles évoluer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent subir des mutations au fil du temps, affectant leur comportement."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications lors de l'utilisation des lignées cellulaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial de suivre des protocoles stricts de culture et de manipulation."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires peuvent-elles induire des complications cliniques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne sont pas utilisées directement en clinique et ne causent pas de complications."
}
},
{
"@type": "Question",
"name": "Les complications des lignées cellulaires affectent-elles la recherche ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications peuvent compromettre la validité des résultats de recherche."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec les lignées cellulaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques, environnementaux et comportementaux sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires peuvent-elles aider à identifier des facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles permettent d'étudier les mécanismes sous-jacents des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment les lignées cellulaires contribuent-elles à la compréhension des risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à modéliser l'impact des facteurs de risque sur la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Peut-on tester des interventions préventives sur des lignées cellulaires ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interventions peuvent être testées pour évaluer leur impact sur les risques."
}
},
{
"@type": "Question",
"name": "Les lignées cellulaires tumorales révèlent-elles des risques spécifiques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent aider à identifier des risques spécifiques liés à certains types de cancer."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/03/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Publications dans "Lignée cellulaire tumorale" :
4 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
4 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
4 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
4 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
4 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. takondo@ncc.go.jp.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Department of Vascular Surgery, Medical University of Vienna, A-1090 Vienna, Austria. barbara.a.rath@meduniwien.ac.at.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, A-1090 Vienna, Austria. lukas.klameth@gmail.com.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Department of Vascular Surgery, Medical University of Vienna, A-1090 Vienna, Austria. adelina.plangger@toc.lbg.ac.at.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Respiratory Oncology Unit, Otto Wagner Hospital, A-1140 Vienna, Austria. maximilian.hochmair@wienkav.at.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Hospital Horn, A-3580 Horn, Austria. ernst.ulsperger@aon.at.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Department of Vascular Surgery, Medical University of Vienna, A-1090 Vienna, Austria. gerhard.hamilton@meduniwien.ac.at.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
3 publications dans cette catégorie
Affiliations :
Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Publications dans "Lignée cellulaire tumorale" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine II, Hematology/Oncology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
German Cancer Research Center and German Cancer Consortium, 69120 Heidelberg, Germany.
Publications dans "Lignée cellulaire tumorale" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine II, Hematology/Oncology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
German Cancer Research Center and German Cancer Consortium, 69120 Heidelberg, Germany.
Publications dans "Lignée cellulaire tumorale" :
2 publications dans cette catégorie
Affiliations :
Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center-Gynecological Cancer Unit, Medical University of Vienna, A-1090 Vienna, Austria. robert.zeillinger@meduniwien.ac.at.
Publications dans "Lignée cellulaire tumorale" :
2 publications dans cette catégorie
Affiliations :
Montville, NJ, United States.
Publications dans "Lignée cellulaire tumorale" :
2 publications dans cette catégorie
Affiliations :
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
The Department of Orthopaedic Surgery, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-0856, Japan.
Publications dans "Lignée cellulaire tumorale" :
The prevalence of metabolic syndrome is increasing worldwide. Clinical guidelines consider metabolic syndrome as an all or none medical condition. One proposed method for classifying metabolic syndrom...
In this study, we used data from the Tehran Lipid and Glucose Cohort Study (TLGS). 4857 participants aged over 20 years with complete information on exposure (smoking) and confounders in the third pha...
Based on the results of IPTW which compared the low, medium and high risk classes of metabolic syndrome (compared to a class without metabolic syndrome), no association was found between smoking and t...
Based on the results, the causal effect of smoking on latent hazard classes of metabolic syndrome can be different based on the type of PS method. In adjusted analysis, no relationship was observed be...
Latent class analysis (LCA) offers a powerful analytical approach for categorizing groups (or "classes") within a heterogenous population. LCA identifies these hidden classes by a set of predefined fe...
Borderline personality disorder (BPD) is characterized by instability in interpersonal, affective, cognitive, self-identity, and behavioral domains. For a BPD diagnosis, individuals must present at le...
South Africa has the largest burden of HIV worldwide and has a growing burden of non-communicable diseases; the combination of which may lead to diseases clustering in ways that are not seen in other ...
Data were analyzed from the South African Demographic and Health Survey 2016. A latent class analysis (LCA) was conducted using nine disease conditions. Sociodemographic and behavioral factors associa...
Multimorbid participants were included (...
This study affirmed that integrated care is urgently needed, evidenced by the largest disease class being an overlap of chronic infectious diseases and non-communicable diseases. This study also highl...
We propose a two-step estimator for multilevel latent class analysis (LCA) with covariates. The measurement model for observed items is estimated in its first step, and in the second step covariates a...
Neonatal risk factors, such as preterm birth and low birth weight, have been robustly linked to neurodevelopmental deficits, yet it is still unclear why some infants born preterm and/or low birth weig...
Neonates who received neonatal care at an academic public hospital during an almost 10-year period (n = 19,951) were included in the latent class analysis, and 21 neonatal indicators of health were us...
The best fitting model included five infant classes: healthy, hypoxic, critically ill, minorly ill, and complicated delivery. Scores on the parent-rated neurodevelopmental measure differed by class su...
The current study extends the understanding of risk factors in neurodevelopment by including several neonatal medical conditions that are often overlooked and by using a person-centered, as opposed to...
An intersectionality framework recognizes individuals as simultaneously inhabiting multiple intersecting social identities embedded within systems of disadvantage and privilege. Previous research link...
We analyzed data from a cohort of 2,286 pregnant participants (Black, n = 933; Hispanic, n = 471; White, n = 853; and Other, n = 29) from the Centering and Racial Disparities trial. Perceived discrimi...
Four discrimination subgroups were identified: no discrimination, general discrimination, discrimination attributed to one or several social identities, and discrimination attributed to most or all so...
Perceived discrimination may play an influential role in shaping perinatal health. More research applying an intersectional lens to the study of discrimination and perinatal health outcomes is needed....
Recent studies have shown that anticoagulant therapy has heterogeneous treatment effects on patients with sepsis-induced coagulopathy (SIC)....
To identify the latent phenotypes of patients with SIC....
Retrospective cohort study....
We obtained data of patients with SIC from the Medical Information Mart for Intensive Care IV database. SIC subphenotypes were identified by latent class analysis (LCA) and K-means clustering. Clinica...
We identified 4,993 patients with SIC. The LCA and K-means clustering analysis robustly identified three subphenotypes of SIC. Class 1 patients (n = 1,808) had the lowest blood cell counts (leukocytes...
Three SIC subphenotypes were defined using clinical findings and laboratory variables. The effects of heparin treatment differ between the subphenotypes. This finding will facilitate the identificatio...
Despite evidence demonstrating the effectiveness of the COVID-19 vaccine, vaccine hesitancy has emerged as a major challenge for vaccine uptake. The objective of this study was to classify latent typo...
We employed a cross-sectional household survey among 1,112 individuals aged 18 and above who were partially vaccinated (one dose) or not vaccinated at the time of the survey. Data was collected in Aug...
Using latent class analysis we found a four-class solution for vaccine hesitancy typologies. The identified classes were strong vaccine acceptors (30%); vaccine acceptors with some concerns (7%); vacc...
Half of the study participants were in the vaccine rejectors class. Individuals in the vaccine sceptics and rejector classes evidenced lower vaccine knowledge and worse COVD-19 prevention practices an...
General practitioners (GPs) were on the front line of the COVID-19 outbreak. Identifying clinical profiles in COVID-19 might improve patient care and enable closer monitoring of at-risk profiles....
To identify COVID-19 profiles in a population of adult primary care patients, and to determine whether the profiles were associated with negative outcomes and persistent symptoms....
In a prospective multicentre study, 44 GPs from multiprofessional primary care practices in the Paris area of France recruited 340 consecutive adult patients (median age: 47 years) with a confirmed di...
A latent class (LC) analysis with 11 indicators (clinical signs and symptoms) was performed. The resulting profiles were characterised by a 3-month composite outcome (COVID-19-related hospital admissi...
We identified six profiles: 'paucisymptomatic' (LC1, 9%), 'anosmia and/or ageusia' (LC2, 12.9%), 'influenza-like syndrome with anosmia and ageusia' (LC3, 15.5%), 'influenza-like syndrome without anosm...
Our findings might help GPs to identify patients at risk of persistent COVID-19 symptoms and hospital admission and then set up procedures for closer monitoring....